Details of the Drug

General Information of Drug (ID: DM4M1SG)

Drug Name
Clarithromycin
Synonyms
Abbotic; Adel; Astromen; Biaxin; Bicrolid; CTY; Clacine; Clambiotic; Claribid; Claricide; Clarith; Clarithromycina; Clarithromycine; Clarithromycinum; Claritromicina; Clathromycin; Cyllid; Cyllind; Helas; Heliclar; Klacid; Klaciped; Klaricid; Klarid; Klarin; Klax; Kofron; Mabicrol; Macladin; Maclar; Mavid; Naxy;Veclam; Zeclar; Biaxin HP; Biaxin XL; Biaxin filmtab; Biaxin xl filmtab; Clarithromycin extended release; Clarithromycin suspension or tablets; Klaricid Pediatric; Klaricid XL; TE031; A-56268; ANX-015; Abbott-56268; Biaxin (TN); Clacid (TN); Claridar (TN); Claripen (TN); Clarithromycine [INN-French]; Clarithromycinum [INN-Latin]; Claritromicina [INN-Spanish]; Crixan (TN); DRG-0099; Fromilid (TN);Infex (TN); Klabax (TN); Klaricid (TN); Klaricid H.P; Lactoferrin B & Clarithromycin; Lactoferrin H & Clarithromycin; SDP-015; TE-031; Vikrol (TN); CLM & IL-12; CRL-1605 & Clarithromycin; Clarithromycin & Interleukin-12; Klaricid H.P.; O(6)-methylerythromycin; Clarithromycin (JP15/USP/INN); Clarithromycin [USAN:INN:BAN:JAN]; Hydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame; (14R)-14-Hydroxyclarithromycin; 6-O-Methylerythromycin; 6-O-Methylerythromycin a
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1]
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 748
Topological Polar Surface Area (xlogp) 3.2
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 14
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
Bioavailability
55% of drug becomes completely available to its intended biological destination(s) [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 7.3 mL/min/kg [4]
Elimination
35% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.8 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.13677 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.23% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.5 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 2 mg/mL [2]
Chemical Identifiers
Formula
C38H69NO13
IUPAC Name
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
Canonical SMILES
CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O
InChI
InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
InChIKey
AGOYDEPGAOXOCK-KCBOHYOISA-N
Cross-matching ID
PubChem CID
84029
ChEBI ID
CHEBI:3732
CAS Number
81103-11-9
DrugBank ID
DB01211
TTD ID
D0Z1ZM
VARIDT ID
DR00713
INTEDE ID
DR0336
ACDINA ID
D00134

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial 50S ribosomal RNA (Bact 50S rRNA) TTUWYEA NOUNIPROTAC Binder [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [8]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [9]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Clarithromycin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Dalfopristin DM4LTKV Moderate Decreased metabolism of Clarithromycin caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [53]
Coadministration of a Drug Treating the Disease Different from Clarithromycin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Decreased metabolism of Clarithromycin caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [54]
Midostaurin DMI6E0R Major Decreased metabolism of Clarithromycin caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [55]
Arn-509 DMT81LZ Moderate Increased metabolism of Clarithromycin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [56]
Gilteritinib DMWQ4MZ Major Decreased metabolism of Clarithromycin caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [57]
Oliceridine DM6MDCF Major Decreased metabolism of Clarithromycin caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [58]
Ivabradine DM0L594 Major Decreased metabolism of Clarithromycin caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [59]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Clarithromycin and Bepridil. Angina pectoris [BA40] [60]
Dronedarone DMA8FS5 Major Decreased metabolism of Clarithromycin caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [59]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Clarithromycin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [61]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Posaconazole. Aspergillosis [1F20] [60]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Clarithromycin and Levalbuterol. Asthma [CA23] [62]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Clarithromycin and Pirbuterol. Asthma [CA23] [63]
Budesonide DMJIBAW Major Decreased metabolism of Clarithromycin caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [64]
Aminophylline DML2NIB Moderate Decreased metabolism of Clarithromycin caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [65]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Retigabine. Behcet disease [4A62] [60]
Cariprazine DMJYDVK Major Decreased metabolism of Clarithromycin caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [66]
Erdafitinib DMI782S Major Decreased metabolism of Clarithromycin caused by Erdafitinib mediated inhibition of CYP450 enzyme. Bladder cancer [2C94] [67]
Pexidartinib DMS2J0Z Major Decreased metabolism of Clarithromycin caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [68]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Eribulin. Breast cancer [2C60-2C6Y] [60]
Talazoparib DM1KS78 Major Decreased clearance of Clarithromycin due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [56]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Clarithromycin caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [69]
Lapatinib DM3BH1Y Major Decreased metabolism of Clarithromycin caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [59]
HKI-272 DM6QOVN Major Decreased metabolism of Clarithromycin caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [70]
LY2835219 DM93VBZ Major Decreased metabolism of Clarithromycin caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [71]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Clarithromycin caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [59]
Tucatinib DMBESUA Moderate Decreased metabolism of Clarithromycin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [72]
Palbociclib DMD7L94 Major Decreased metabolism of Clarithromycin caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [73]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Clarithromycin caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [59]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Clarithromycin caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [59]
Bosutinib DMTI8YE Major Decreased metabolism of Clarithromycin caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [59]
Trastuzumab Emtansine DMU1LXS Moderate Decreased metabolism of Clarithromycin caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [59]
Macitentan DMP79A1 Major Decreased metabolism of Clarithromycin caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [74]
PF-04449913 DMSB068 Major Decreased metabolism of Clarithromycin caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [75]
Vilanterol DMF5EK1 Moderate Decreased metabolism of Clarithromycin caused by Vilanterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [76]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Clarithromycin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [63]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [63]
Levomilnacipran DMV26S8 Major Decreased metabolism of Clarithromycin caused by Levomilnacipran mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [77]
Fidaxomicin DMFP6MV Minor Decreased clearance of Clarithromycin due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [78]
Regorafenib DMHSY1I Moderate Decreased metabolism of Clarithromycin caused by Regorafenib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [59]
Intedanib DMSTA36 Moderate Decreased metabolism of Clarithromycin caused by Intedanib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [79]
Drospirenone DM1A9W3 Major Decreased metabolism of Clarithromycin caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [59]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Clarithromycin caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [59]
Ulipristal DMBNI20 Minor Decreased metabolism of Clarithromycin caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [56]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Sevoflurane. Corneal disease [9A76-9A78] [60]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Probucol. Coronary atherosclerosis [BA80] [60]
Oxtriphylline DMLHSE3 Moderate Decreased metabolism of Clarithromycin caused by Oxtriphylline mediated inhibition of CYP450 enzyme. Cough [MD12] [65]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Clarithromycin and Pasireotide. Cushing syndrome [5A70] [60]
Osilodrostat DMIJC9X Major Decreased metabolism of Clarithromycin caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [56]
Ivacaftor DMZC1HS Major Decreased metabolism of Clarithromycin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [59]
MK-8228 DMOB58Q Moderate Decreased metabolism of Clarithromycin caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [80]
Rivaroxaban DMQMBZ1 Moderate Decreased clearance of Clarithromycin due to the transporter inhibition by Rivaroxaban. Deep vein thrombosis [BD71] [81]
Vilazodone DM4LECQ Major Decreased metabolism of Clarithromycin caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [82]
OPC-34712 DMHG57U Major Decreased metabolism of Clarithromycin caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [83]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Clomipramine. Depression [6A70-6A7Z] [60]
Polatuzumab vedotin DMF6Y0L Major Decreased metabolism of Clarithromycin caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [84]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Clarithromycin caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [59]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [60]
Ospemifene DMC4GEI Moderate Decreased metabolism of Clarithromycin caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [85]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Deutetrabenazine. Dystonic disorder [8A02] [86]
Ingrezza DMVPLNC Major Additive CNS depression effects by the combination of Clarithromycin and Ingrezza. Dystonic disorder [8A02] [87]
Cenobamate DMGOVHA Moderate Increased metabolism of Clarithromycin caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [88]
Stiripentol DMMSDOY Moderate Decreased metabolism of Clarithromycin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [56]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Clarithromycin caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [89]
Lacosamide DMVM6QR Moderate Decreased metabolism of Clarithromycin caused by Lacosamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [59]
Cannabidiol DM0659E Minor Decreased metabolism of Clarithromycin caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [56]
Bay 80-6946 DMLOS5R Major Decreased metabolism of Clarithromycin caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [90]
Tazemetostat DMWP1BH Major Decreased metabolism of Clarithromycin caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [91]
Solifenacin DMG592Q Major Decreased metabolism of Clarithromycin caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [59]
Mirabegron DMS1GYT Minor Decreased metabolism of Clarithromycin caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [92]
Dexlansoprazole DM1DBV5 Moderate Decreased metabolism of Clarithromycin caused by Dexlansoprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [93]
Ripretinib DM958QB Major Decreased metabolism of Clarithromycin caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [59]
Sunitinib DMCBJSR Moderate Decreased metabolism of Clarithromycin caused by Sunitinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [59]
Avapritinib DMK2GZX Major Decreased metabolism of Clarithromycin caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [56]
Colchicine DM2POTE Major Decreased metabolism of Clarithromycin caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [94]
Digitoxin DMWVIGP Moderate Decreased clearance of Clarithromycin due to the transporter inhibition by Digitoxin. Heart failure [BD10-BD1Z] [95]
Boceprevir DMBSHMF Moderate Decreased metabolism of Clarithromycin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [96]
Simeprevir DMLUA9D Major Decreased metabolism of Clarithromycin caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [59]
Telaprevir DMMRV29 Moderate Decreased metabolism of Clarithromycin caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [96]
Daclatasvir DMSFK9V Major Decreased metabolism of Clarithromycin caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [56]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Clarithromycin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [97]
MK-1439 DM215WE Minor Decreased metabolism of Clarithromycin caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [98]
Fosamprenavir DM4W9B3 Minor Decreased metabolism of Clarithromycin caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [99]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [100]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Clarithromycin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [59]
Dolutegravir DMCZGRE Minor Decreased metabolism of Clarithromycin caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [101]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Clarithromycin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [102]
Etravirine DMGV8QU Moderate Increased metabolism of Clarithromycin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [103]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Clarithromycin caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [104]
Darunavir DMN3GCH Moderate Decreased metabolism of Clarithromycin caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [105]
Maraviroc DMTL94F Major Decreased metabolism of Clarithromycin caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [106]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Clarithromycin and Mipomersen. Hyper-lipoproteinaemia [5C80] [107]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Clarithromycin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [60]
BMS-201038 DMQTAGO Major Decreased metabolism of Clarithromycin caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [59]
Aliskiren DM1BV7W Moderate Decreased metabolism of Clarithromycin caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [60]
Levamlodipine DM92S6N Moderate Decreased metabolism of Clarithromycin caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [60]
Tolvaptan DMIWFRL Major Decreased metabolism of Clarithromycin caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [59]
Retapamulin DM9JXB7 Minor Decreased metabolism of Clarithromycin caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [108]
TP-434 DM5A31S Minor Decreased metabolism of Clarithromycin caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [109]
Berotralstat DMWA2DZ Major Decreased clearance of Clarithromycin due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [110]
Suvorexant DM0E6S3 Major Decreased metabolism of Clarithromycin caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [59]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Clarithromycin caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [111]
ITI-007 DMUQ1DO Major Decreased metabolism of Clarithromycin caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [112]
Quazepam DMY4D87 Moderate Decreased metabolism of Clarithromycin caused by Quazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [113]
Estazolam DMZGXUM Moderate Decreased metabolism of Clarithromycin caused by Estazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [113]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Clarithromycin and Polyethylene glycol. Irritable bowel syndrome [DD91] [56]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Clarithromycin and Phenolphthalein. Irritable bowel syndrome [DD91] [60]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Clarithromycin caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [114]
Naloxegol DML0B41 Major Decreased metabolism of Clarithromycin caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [59]
Pemigatinib DM819JF Major Decreased metabolism of Clarithromycin caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [56]
Crizotinib DM4F29C Major Decreased metabolism of Clarithromycin caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [59]
Brigatinib DM7W94S Major Decreased metabolism of Clarithromycin caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [115]
Ceritinib DMB920Z Major Decreased metabolism of Clarithromycin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [59]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Clarithromycin caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [116]
Osimertinib DMRJLAT Major Decreased metabolism of Clarithromycin caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [117]
Pralsetinib DMWU0I2 Major Decreased clearance of Clarithromycin due to the transporter inhibition by Pralsetinib. Lung cancer [2C25] [118]
Capmatinib DMYCXKL Major Decreased metabolism of Clarithromycin caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [119]
Selpercatinib DMZR15V Major Decreased metabolism of Clarithromycin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [56]
Artemether DM48QOT Major Decreased metabolism of Clarithromycin caused by Artemether mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [59]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Clarithromycin and Halofantrine. Malaria [1F40-1F45] [120]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Clarithromycin and Hydroxychloroquine. Malaria [1F40-1F45] [121]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [56]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Clarithromycin and Idelalisib. Mature B-cell leukaemia [2A82] [122]
GDC-0199 DMH0QKA Major Decreased metabolism of Clarithromycin caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [123]
Acalabrutinib DM7GCVW Major Decreased metabolism of Clarithromycin caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [124]
Ibrutinib DMHZCPO Major Decreased metabolism of Clarithromycin caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [59]
Ponatinib DMYGJQO Major Decreased metabolism of Clarithromycin caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [59]
Arry-162 DM1P6FR Moderate Decreased clearance of Clarithromycin due to the transporter inhibition by Arry-162. Melanoma [2C30] [59]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Clarithromycin and Vemurafenib. Melanoma [2C30] [60]
Selumetinib DMC7W6R Major Decreased metabolism of Clarithromycin caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [125]
LGX818 DMNQXV8 Major Decreased metabolism of Clarithromycin caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [126]
Dabrafenib DMX6OE3 Moderate Decreased metabolism of Clarithromycin caused by Dabrafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [59]
Ubrogepant DM749I3 Major Decreased metabolism of Clarithromycin caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [127]
Rimegepant DMHOAUG Moderate Decreased metabolism of Clarithromycin caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [128]
Exjade DMHPRWG Moderate Decreased metabolism of Clarithromycin caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [129]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Clarithromycin and Siponimod. Multiple sclerosis [8A40] [59]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Clarithromycin and Fingolimod. Multiple sclerosis [8A40] [60]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Clarithromycin and Ozanimod. Multiple sclerosis [8A40] [130]
Deflazacort DMV0RNS Major Decreased metabolism of Clarithromycin caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [56]
Romidepsin DMT5GNL Moderate Decreased metabolism of Clarithromycin caused by Romidepsin mediated inhibition of CYP450 enzyme. Mycosis fungoides [2B01] [131]
Fedratinib DM4ZBK6 Major Decreased metabolism of Clarithromycin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [56]
Nilotinib DM7HXWT Major Decreased metabolism of Clarithromycin caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [59]
Dasatinib DMJV2EK Major Decreased metabolism of Clarithromycin caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [59]
Vorapaxar DMA16BR Major Decreased metabolism of Clarithromycin caused by Vorapaxar mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [59]
E-2007 DMJDYNQ Minor Decreased metabolism of Clarithromycin caused by E-2007 mediated inhibition of CYP450 enzyme. Neuropathy [8C0Z] [56]
Entrectinib DMMPTLH Major Decreased metabolism of Clarithromycin caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [59]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Clarithromycin and Levomethadyl Acetate. Opioid use disorder [6C43] [56]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Lofexidine. Opioid use disorder [6C43] [60]
S-297995 DM26IH8 Moderate Decreased metabolism of Clarithromycin caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [56]
Olaparib DM8QB1D Major Decreased metabolism of Clarithromycin caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [59]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Rucaparib. Ovarian cancer [2C73] [60]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Triclabendazole. Parasitic worm infestation [1F90] [60]
Istradefylline DM20VSK Major Decreased metabolism of Clarithromycin caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [132]
Abametapir DM2RX0I Moderate Decreased metabolism of Clarithromycin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [133]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Clarithromycin and Macimorelin. Pituitary gland disorder [5A60-5A61] [134]
Lefamulin DME6G97 Major Decreased metabolism of Clarithromycin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [135]
Ergonovine DM0VEC1 Major Decreased metabolism of Clarithromycin caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [136]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Clarithromycin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [137]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Degarelix. Prostate cancer [2C82] [56]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and ABIRATERONE. Prostate cancer [2C82] [56]
Enzalutamide DMGL19D Moderate Increased metabolism of Clarithromycin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [138]
Relugolix DMK7IWL Major Decreased metabolism of Clarithromycin caused by Relugolix mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [139]
Silodosin DMJSBT6 Major Decreased metabolism of Clarithromycin caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [59]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Levomepromazine. Psychotic disorder [6A20-6A25] [60]
Ambrisentan DMD1QXW Minor Decreased metabolism of Clarithromycin caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [140]
Riociguat DMXBLMP Moderate Decreased clearance of Clarithromycin due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [59]
Everolimus DM8X2EH Major Decreased clearance of Clarithromycin due to the transporter inhibition by Everolimus. Renal cell carcinoma [2C90] [59]
Axitinib DMGVH6N Major Decreased metabolism of Clarithromycin caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [59]
Temsirolimus DMS104F Major Increased metabolism of Clarithromycin caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [59]
Ciclesonide DM2NA4K Moderate Decreased metabolism of Clarithromycin caused by Ciclesonide mediated inhibition of CYP450 enzyme. Respiratory system disease [CB40-CB7Z] [141]
Upadacitinib DM32B5U Major Decreased metabolism of Clarithromycin caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [142]
Tofacitinib DMBS370 Major Decreased metabolism of Clarithromycin caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [59]
Dexamethasone DMMWZET Moderate Decreased metabolism of Clarithromycin caused by Dexamethasone mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [141]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Clarithromycin and Quetiapine. Schizophrenia [6A20] [143]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Clarithromycin caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [144]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Clarithromycin and Iloperidone. Schizophrenia [6A20] [60]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Paliperidone. Schizophrenia [6A20] [60]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Clarithromycin and Amisulpride. Schizophrenia [6A20] [145]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Asenapine. Schizophrenia [6A20] [60]
Avanafil DM75CXN Major Decreased metabolism of Clarithromycin caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [59]
Voxelotor DMCS6M5 Major Decreased metabolism of Clarithromycin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [146]
LDE225 DMM9F25 Major Decreased metabolism of Clarithromycin caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [147]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Clarithromycin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [56]
Larotrectinib DM26CQR Major Decreased metabolism of Clarithromycin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [59]
Docetaxel DMDI269 Major Decreased metabolism of Clarithromycin caused by Docetaxel mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [148]
Trabectedin DMG3Y89 Major Decreased metabolism of Clarithromycin caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [59]
Armodafinil DMGB035 Minor Decreased metabolism of Clarithromycin caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [59]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Clarithromycin and LEE011. Solid tumour/cancer [2A00-2F9Z] [149]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Clarithromycin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [60]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [56]
Taxol DMUOT9V Moderate Decreased metabolism of Clarithromycin caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [150]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Pitolisant. Somnolence [MG42] [60]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [60]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Clarithromycin caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [59]
Fostamatinib DM6AUHV Major Decreased metabolism of Clarithromycin caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [151]
As-1670542 DMV05SW Moderate Decreased metabolism of Clarithromycin caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [56]
Apixaban DM89JLN Moderate Decreased clearance of Clarithromycin due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [59]
Brilinta DMBR01X Major Decreased metabolism of Clarithromycin caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [59]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Lenvatinib. Thyroid cancer [2D10] [60]
Cabozantinib DMIYDT4 Major Decreased metabolism of Clarithromycin caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [59]
Saxagliptin DMGXENV Moderate Decreased metabolism of Clarithromycin caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [56]
Elagolix DMB2C0E Major Decreased metabolism of Clarithromycin caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [152]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Clarithromycin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [153]
Fluticasone DMGCSVF Major Decreased metabolism of Clarithromycin caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [154]
⏷ Show the Full List of 203 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Cis-vanillin 2,3-butanediol acetal E00595 71587693 Flavoring agent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Glyceryl monostearate E00310 24699 Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Hydrazine yellow E00409 164825 Colorant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Quinoline yellow WS E00309 24671 Colorant
Sodium stearyl fumarate E00545 23665634 lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Vanillin E00049 1183 Flavoring agent
Carmellose sodium E00625 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium hydroxide E00374 73981 Adsorbent; Buffering agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium sorbate E00566 23676745 Antimicrobial preservative
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Propylene glycol distearate E00395 110800 Emollient; Opacifying agent; Surfactant
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sorbic acid E00441 643460 Antimicrobial preservative
Sorbitan monooleate E00503 9920342 Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Sucrose 1,6-distearate E00593 71587490 Dispersing agent; Emulsifying agent; Modified-release agent; Solubilizing agent; Surfactant; lubricant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 39 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Clarithromycin 500 mg tablet 500 mg 24 HR Extended Release Oral Tablet Oral
Clarithromycin 250 mg tablet 250 mg Oral Tablet Oral
Clarithromycin 500 mg tablet 500 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
7 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
8 Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. J Cyst Fibros. 2014 Mar;13(2):179-85.
9 Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol. 2005 Jun;3(6):564-73.
10 Drug Interactions Flockhart Table
11 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
21 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
22 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
23 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
24 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
25 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
26 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
27 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
28 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
29 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
30 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
31 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
32 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
33 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
34 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
35 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
36 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
37 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
38 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
39 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
40 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
41 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
42 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
43 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
44 A synthetic alanyl-initiator tRNA with initiator tRNA properties as determined by fluorescence measurements: comparison to a synthetic alanyl-elongator tRNA. Nucleic Acids Res. 1991 Oct 25;19(20):5749-54.
45 An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol. 2004 Oct;49(4):239-47.
46 Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61(4):443-98.
47 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
48 Depression of colony formation by human thymus-derived lymphocytes with rifampin and other antimicrobial agents. J Infect Dis. 1981 Jun;143(6):832-5.
49 Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007 Sep;51(9):3385-7.
50 The streptogramin antibiotics: update on their mechanism of action. Expert Opin Investig Drugs. 1998 Apr;7(4):591-9.
51 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
52 The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J Mol Biol. 2002 Sep 13;322(2):273-9.
53 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
54 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
55 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
56 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
57 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
58 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
59 Cerner Multum, Inc. "Australian Product Information.".
60 Canadian Pharmacists Association.
61 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
62 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
63 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
64 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
65 Amsden GW "Erythromycin, clarithromycin, and azithromycin: are the differences real?" Clin Ther 18 (1996): 56-72. [PMID: 8851453]
66 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
67 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
68 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
69 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
70 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
71 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
72 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
73 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
74 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
75 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
76 Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
77 Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
78 Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
79 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
80 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
81 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
82 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
83 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
84 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
85 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
86 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
87 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
88 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
89 Bachmann K, Schwartz JI, Forney RB Jr, Jauregui L "Single dose phenytoin clearance during erythromycin treatment." Res Commun Chem Pathol Pharmacol 46 (1984): 207-17. [PMID: 6515115]
90 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
91 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
92 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
93 Miura M, Tada H, Yasui-Furukori N, et al. "Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes." Chirality 17 (2005): 338-344. [PMID: 15856433]
94 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
95 Hughes J, Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.?J Pharmacol Sci. 2010;113(4):315-324. [PMID: 20724802]
96 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
97 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
98 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
99 Polk RE, Crouch MA, Israel DS, et al. "Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men." Pharmacotherapy 19 (1999): 1378-84. [PMID: 10600086]
100 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
101 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
102 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
103 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
104 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
105 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
106 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
107 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
108 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
109 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
110 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
111 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
112 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
113 Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
114 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
115 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
116 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
117 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
118 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
119 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
120 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
121 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
122 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
123 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
124 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
125 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
126 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
127 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
128 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
129 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
130 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
131 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
132 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
133 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
134 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
135 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
136 Matthews NT, Havill JH "Ergotism with therapeutic doses of ergotamine tartrate." N Z Med J 89 (1979): 476-7. [PMID: 314074]
137 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
138 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
139 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
140 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
141 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
142 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
143 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
144 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
145 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
146 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
147 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
148 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
149 Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
150 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
151 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
152 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
153 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
154 Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]